A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
Completed
Sunovion
Phase 1
This is a single-center, randomized, single-blind, placebo-controlled, ascending single oral
dose study designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles
of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia.
Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics
Completed
Sunovion
Phase 1
This study is designed to evaluate the effects of a single dose of SEP-363856 in healthy male
and female volunteers with high or low schizotype characteristics.
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
Completed
Sunovion
Phase 1
This is a study designed to evaluate the safety, tolerability, and PK of SEP-363856 and its
metabolite SEP-363854 in male and female subjects with schizophrenia.
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
Completed
Sunovion
Phase 2
A study to evaluate the safety and tolerability of SEP363856 in subjects with Parkinson's
Disease Psychosis. This study is accepting male and female participants 55 years of age and
older who have been diagnosed with Parkinson's Disease. This study will be conducted in 24
study centers in the United States. The study will last approximately 21 weeks
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
